CARSON CITY, Nev. , Oct. 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the Company has been invited to present at the 2026 RECOVER–Treating Long COVID (RECOVER-TLC) Hybrid Workshop, hosted by the National Institute of Allergy and Infectious Diseases (NIAID) and the Foundation for the National Institutes of Health (FNIH) from November 4–5, 2026, in Bethesda, Maryland . Dr. Penelope Markham , BioVie’s Senior Vice President and Program Lead for Long COVID, will share results from the Company’s Phase 2 ADDRESS-LC trial evaluating bezisterim for the treatment of the neurological symptoms of Long COVID at the “Recent Insights from Long COVID Clinical Trials” Panel Discussion on Thursday, November 5 , being held from 9:10 –10:10 a.m. ET. The 2026 RECOVER-TLC hybrid workshop will provide updates on RECOVER-TLC clinical trials and emerging discoveries in Long COVID research. The event will also provide opportunities for community members to help inform future research priorities for RECOVER-TLC clinical trials. The RECOVER-TLC Initiative was launched to accelerate the development of treatments for Long COVID, recognizing that millions of people continue to experience persistent symptoms following COVID-19 infection and that no therapies have yet been approved. To date, RECOVER-TLC has advanced four therapeutic candidates into clinical testing and continues to evaluate additional promising interventions for this underserved patient population. The ADDRESS-LC trial showed treatment with bezisterim showed a consistent trend toward improvement across most patient-reported and objective efficacy measures compared with placebo. Patients with more severe baseline fatigue, post-exertional malaise (PEM), or objective cognitive impairment – symptoms affecting approximately 78% of trial participants in at least one domain – experienced the greatest benefits with bezisterim, including statistically significant improvements in multiple measures corresponding to their most pronounced symptoms. Bezisterim’s safety and tolerability profile in the trial was similar to placebo. “We observed a consistent and clinically coherent pattern of improvement across measures of fatigue, post-exertional malaise, clinician- and patient-reported outcomes, and objective measures of cognitive function among patients with greater baseline symptom burden,” said Dr. Penelope Markham . “These findings provide valuable insights into which patients may benefit most from bezisterim and provide an important foundation for the design of a confirmatory Phase 3 study.” About Long COVID An estimated 17-20 million U.S . adults reported to be living with Long COVID,1 with 3.8 million experiencing significant limitation to their daily lives.2 Almost 50 percent of those with Long COVID develop persistent or intermittent symptoms.3 The neurological and neuropsychiatric symptoms are among the most common and disabling manifestations of the condition and include fatigue, PEM, sleep disturbance, and persistent sense of difficulty with thinking and memory.4 Chronic innate inflammation accompanied by ongoing immune dysregulation is among the leading hypotheses proposed to explain the symptoms in Long COVID, with numerous investigators describing findings in Long COVID that appear to be supportive of the intended biological targets of bezisterim. Currently, there are no FDA-approved treatment options for Long-COVID. About the ADDRESS-LC trial The Phase 2 ADDRESS-LC study ( NCT06847191 ), which is fully funded by a grant from the U.S. Department of War (DoW), is a randomized (1:1), placebo-controlled, signal-finding proof-of-concept, multicenter trial evaluating the efficacy, safety and tolerability of bezisterim in adult participants with Long COVID who have cognitive impairment sequelae and fatigue. The study compared bezisterim, administered as a 20 mg oral capsule twice daily, with a matching placebo to assess its effects on neurocognitive and fatigue-related symptoms. The trial evaluated 22 clinical outcome measures, with no single endpoint pre-specified as the primary determinant of study success. Endpoints include assessing changes in overall clinical benefit, subjective and objective cognitive function, fatigue, sleep disturbance, Quality of Life and PEM. As a signal-finding study, the trial was designed to identify efficacy signals, measure treatment effect magnitude, and identify patient subgroups most likely to benefit, to inform the design of future Phase 3 trials. About Bezisterim Bezisterim (NE3107) is an investigational oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NFκB, TNFα), bezist